Rituximab treatment in patients with refractory inflammatory myopathies.

OBJECTIVE To assess the efficacy of rituximab on disease activity and muscle strength in patients with inflammatory myopathies refractory to conventional therapy. METHODS; Thirteen patients were treated with rituximab 1000 mg i.v., twice, with a 2-week interval and followed for a median of 27 months. Primary outcomes were disease activity measured by creatine phosphokinase (CPK), lactate dehydrogenase (LDH) levels and muscle strength measured by hand-held dynamometry and manual muscle testing (MMT). Secondary outcomes were improvement in secondary laboratory measures, global assessment of general health, disease activity and pain, CS dose, functional ability, health-related quality of life and safety. Retreatment with rituximab was conducted if disease activity relapsed. RESULTS; The median levels of CPK and LDH were significantly reduced by 93.2 and 39.8%, respectively, compared with baseline after 34.6 months. The median muscle strength measured by hand-held dynamometry was significantly improved by 21.5% after 24 months. The median increase in muscle strength measured with MMT was 7.0% after 24 months of follow-up, although this did not reach statistical significance. Secondary outcomes improved as well. CONCLUSION; Rituximab is an effective treatment in refractory inflammatory myopathies, showing a decrease in CPK and LDH, an increase in muscle strength and improvement in scores of disease activity, general health, functional ability and health related quality of life with sustained effect during a median of 27.1 months of follow-up.

[1]  D. Isenberg,et al.  Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. , 2008, Clinical and experimental rheumatology.

[2]  M. Dougados,et al.  Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. , 2007, Arthritis and rheumatism.

[3]  C. Salvarani,et al.  Established and new treatments of the idiopathic inflammatory myopathies: dermatomyositis and polymyositis. , 2007, Clinical and experimental rheumatology.

[4]  I. Lundberg,et al.  Disease-specific quality indicators, outcome measures and guidelines in polymyositis and dermatomyositis. , 2007, Clinical and experimental rheumatology.

[5]  C. Mok,et al.  Rituximab for refractory polymyositis: an open-label prospective study. , 2007, The Journal of rheumatology.

[6]  M. Genovese,et al.  A pilot trial of rituximab in the treatment of patients with dermatomyositis. , 2007, Archives of dermatology.

[7]  J. Yazdany,et al.  Six refractory lupus patients treated with rituximab: a case series. , 2007, Arthritis and rheumatism.

[8]  I. Targoff.  Myositis specific autoantibodies , 2006, Current rheumatology reports.

[9]  M. Weinblatt,et al.  Rituximab as therapy for refractory polymyositis and dermatomyositis. , 2006, The Journal of rheumatology.

[10]  C. Gabay,et al.  Rituximab in the treatment of antisynthetase syndrome , 2005, Annals of the rheumatic diseases.

[11]  B. Gruber,et al.  Rituximab in the treatment of refractory dermatomyositis. , 2005, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[12]  O. Lambotte,et al.  Efficacy of rituximab in refractory polymyositis. , 2005, The Journal of rheumatology.

[13]  K. Fujii,et al.  Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. , 2005, Rheumatology.

[14]  T. Levine.  Rituximab in the treatment of dermatomyositis: an open-label pilot study. , 2005, Arthritis and rheumatism.

[15]  P. Lachenbruch,et al.  International consensus on preliminary definitions of improvement in adult and juvenile myositis. , 2004, Arthritis and rheumatism.

[16]  S. Greenberg,et al.  Uncertainties in the pathogenesis of adult dermatomyositis , 2004, Current opinion in neurology.

[17]  D. Ascherman.  The role of jo-1 in the immunopathogenesis of polymyositis: Current hypotheses , 2003, Current rheumatology reports.

[18]  R. Hohlfeld,et al.  Polymyositis and dermatomyositis , 2003, The Lancet.

[19]  J. Biederer,et al.  Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. , 2003, Seminars in arthritis and rheumatism.

[20]  D. Isenberg,et al.  Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. , 2001, Rheumatology.

[21]  P. van Riel,et al.  Health Assessment Questionnaire modifications: is standardisation needed? , 2001, Annals of the rheumatic diseases.

[22]  A. Juul.  Determination of Insulin-Like Growth Factor I in Children: Normal Values and Clinical Use , 2001, Hormone Research in Paediatrics.

[23]  D. Isenberg,et al.  Autoantibody profiles in the sera of European patients with myositis , 2001, Annals of the rheumatic diseases.

[24]  J. Griffin,et al.  Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases , 2001, Neurology.

[25]  J. Vencovský,et al.  The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient , 2000, Annals of the rheumatic diseases.

[26]  D. Reinberg,et al.  The Dermatomyositis-Specific Autoantigen Mi2 Is a Component of a Complex Containing Histone Deacetylase and Nucleosome Remodeling Activities , 1998, Cell.

[27]  B. V. van Engelen,et al.  Frequent occurrence of anti-tRNA(His) autoantibodies that recognize a conformational epitope in sera of patients with myositis. , 1998, Arthritis and rheumatism.

[28]  L. Pachman,et al.  Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis. , 1997, The Journal of rheumatology.

[29]  W H Rogers,et al.  Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. , 1995, Medical care.

[30]  F. Miller,et al.  Laboratory evaluation of the inflammatory myopathies , 1995, Clinical and diagnostic laboratory immunology.

[31]  F. Miller.  Myositis-Specific Autoantibodies: Touchstones for Understanding the Inflammatory Myopathies , 1993 .

[32]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[33]  M. Dalakas,et al.  A New Approach to the Classification of Idiopathic Inflammatory Myopathy: Myositis‐Specific Autoantibodies Define Useful Homogeneous Patient Groups , 1991, Medicine.

[34]  J. Piette,et al.  Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. , 1991, The American journal of medicine.

[35]  V. Fidler,et al.  Hand-held myometry: reference values. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[36]  A. Engel,et al.  Microvascular changes in early and advanced dermatomyositis: A quantitative study , 1990, Annals of neurology.

[37]  J. Fries,et al.  The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. , 1982, The Journal of rheumatology.

[38]  B. V. van Engelen,et al.  Treatment of the inflammatory myopathies: update and practical recommendations. , 2009, Expert opinion on pharmacotherapy.

[39]  Y. Yamasaki,et al.  Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. , 2007, Rheumatology.

[40]  B. Engelen,et al.  Clinical and serological characteristics of 125 Dutch myositis patients , 2002, Journal of Neurology.

[41]  D. Isenberg,et al.  Treatment of dermatomyositis and polymyositis. , 2002, Rheumatology.

[42]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .

[43]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975, The New England journal of medicine.

[44]  A. Bohan,et al.  Polymyositis and dermatomyositis (first of two parts). , 1975, The New England journal of medicine.